DBV Technologies (NASDAQ:DBVT) Posts Quarterly Earnings Results

DBV Technologies (NASDAQ:DBVT) issued its quarterly earnings data on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48), FiscalAI reports. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.78 million.

DBV Technologies Trading Down 5.4%

Shares of DBV Technologies stock traded down $0.85 during trading hours on Thursday, hitting $14.86. 378,468 shares of the company were exchanged, compared to its average volume of 292,122. The business has a 50-day moving average of $17.34 and a 200-day moving average of $19.54. DBV Technologies has a 1 year low of $8.51 and a 1 year high of $26.18. The stock has a market capitalization of $879.86 million, a price-to-earnings ratio of -3.33 and a beta of -0.95.

Institutional Trading of DBV Technologies

Several hedge funds have recently made changes to their positions in DBVT. Royal Bank of Canada acquired a new position in shares of DBV Technologies during the fourth quarter worth about $34,000. Truvestments Capital LLC lifted its position in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the period. Persistent Asset Partners Ltd purchased a new stake in DBV Technologies in the 4th quarter valued at approximately $115,000. Two Sigma Investments LP purchased a new stake in DBV Technologies in the 3rd quarter valued at approximately $167,000. Finally, Citadel Advisors LLC acquired a new stake in shares of DBV Technologies in the 3rd quarter valued at approximately $220,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Guggenheim restated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Finally, HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.